**4. Conclusion**

Psoriasis is characterized by the presence of physical and psychological pains, which can severely affect the quality of life of psoriatic patients. Currently, a broad spectrum of antipsoriatic treatments, both topical and systemic, is available for the management of psoriasis. These treatments only allow to control psoriasis without curing it. Challenges for antipsoriatic-drugs development are numerous, and the pharmaceutical industry strongly

Psoriatic Skin Models: A Need for the Pharmaceutical Industry 59

Chan, J.R., Blumenschein, W., Murphy, E., Diveu, C., Wiekowski, M., Abbondanzo, S.,

Christophers, E., Griffiths, C.E., Gaitanis, G. & van de Kerkhof, P. (2006). The unmet

Cook, P.W., Brown, J.R., Cornell, K.A. & Pittelkow, M.R. (2004). Suprabasal expression of

Cook, P.W., Piepkorn, M., Clegg, C.H., Plowman, G.D., DeMay, J.M., Brown, J.R. &

Danilenko, D.M. (2008). Review paper: preclinical models of psoriasis. *Vet Pathol,* Vol. 45,

DiBonaventura, M., Wagner, S., Waters, H. & Carter, C. (2010). Treatment patterns and

Dubertret, L., Mrowietz, U., Ranki, A., van de Kerkhof, P.C., Chimenti, S., Lotti, T. & Schafer, G.

Farshidi, A. & Sadeghi, P. (2006). Successful treatment of severe refractory atopic dermatitis with efalizumab. *J Drugs Dermatol,* Vol. 5, No. 10, (Nov-Dec), pp. 994-998. Fraki, J.E., Briggaman, R.A. & Lazarus, G.S. (1983). Transplantation of psoriatic skin onto

Gottlieb, A.B., Casale, T.B., Frankel, E., Goffe, B., Lowe, N., Ochs, H.D., Roberts, J.L., Washenik,

Groves, R.W., Mizutani, H., Kieffer, J.D. & Kupper, T.S. (1995). Inflammatory skin disease in

Gudjonsson, J.E., Johnston, A., Dyson, M., Valdimarsson, H. & Elder, J.T. (2007). Mouse models of psoriasis. *J Invest Dermatol,* Vol. 127, No. 6, (Jun), pp. 1292-1308. Guo, L., Yu, Q.C. & Fuchs, E. (1993). Targeting expression of keratinocyte growth factor to

Guttman-Yassky, E. & Krueger, J.G. (2007). Psoriasis: evolution of pathogenic concepts and

with psoriasis. *J Drugs Dermatol,* Vol. 9, No. 8, (Aug), pp. 938-944.

membership survey. *Br J Dermatol,* Vol. 155, No. 4, (Oct), pp. 729-736.

nude mice. *J Invest Dermatol,* Vol. 80 Suppl, No. (Jun), pp. 31s-35s.

*Proc Natl Acad Sci U S A,* Vol. 92, No. 25, (Dec 5), pp. 11874-11878.

*J Am Acad Dermatol,* Vol. 49, No. 5, (Nov), pp. 816-825.

*Embo J,* Vol. 12, No. 3, (Mar), pp. 973-986.

6, (Dec), pp. 1103-1115.

review. *J Eur Acad Dermatol Venereol,* Vol. 20, No. 8, (Sep), pp. 921-925. Conrad, C., Boyman, O., Tonel, G., Tun-Kyi, A., Laggner, U., de Fougerolles, A., Kotelianski,

pp. 2577-2587.

347-356.

2294.

13, No. 7, (Jul), pp. 836-842.

No. 4, (Jul), pp. 563-575.

Lucian, L., Geissler, R., Brodie, S., Kimball, A.B., Gorman, D.M., Smith, K., de Waal Malefyt, R., Kastelein, R.A., McClanahan, T.K. & Bowman, E.P. (2006). IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. *J Exp Med,* Vol. 203, No. 12, (Nov 27),

treatment need for moderate to severe psoriasis: results of a survey and chart

V., Gardner, H. & Nestle, F.O. (2007). Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. *Nat Med,* Vol.

human amphiregulin in the epidermis of transgenic mice induces a severe, earlyonset, psoriasis-like skin pathology: expression of amphiregulin in the basal epidermis is also associated with synovitis. *Exp Dermatol,* Vol. 13, No. 6, (Jun), pp.

Pittelkow, M.R. (1997). Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. *J Clin Invest,* Vol. 100, No. 9, (Nov 1), pp. 2286-

perceptions of treatment attributes, satisfaction and effectiveness among patients

(2006). European patient perspectives on the impact of psoriasis: the EUROPSO patient

K., Vaishnaw, A.K. & Gordon, K.B. (2003). CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study.

transgenic mice that express high levels of interleukin 1 alpha in basal epidermis.

keratinocytes elicits striking changes in epithelial differentiation in transgenic mice.

new therapies through phases of translational research. *Br J Dermatol,* Vol. 157, No.

needs highly predictive *in vivo* and *in vitro* models to improve the success rate of the development of new drugs. Effectively, the lack of representative *in vivo* and *in vitro* models could be related with failures of clinical trials. Thus, the elaboration of these models represents a key component in the fight against psoriasis.

#### **5. References**


needs highly predictive *in vivo* and *in vitro* models to improve the success rate of the development of new drugs. Effectively, the lack of representative *in vivo* and *in vitro* models could be related with failures of clinical trials. Thus, the elaboration of these models

Baker, B.S., Owles, A.V. & Fry, L. (2008). A possible role for vaccination in the treatment of psoriasis? *G Ital Dermatol Venereol,* Vol. 143, No. 2, (Apr), pp. 105-117. Barker, C.L., McHale, M.T., Gillies, A.K., Waller, J., Pearce, D.M., Osborne, J., Hutchinson,

Blessing, M., Schirmacher, P. & Kaiser, S. (1996). Overexpression of bone morphogenetic

Blumberg, H., Conklin, D., Xu, W.F., Grossmann, A., Brender, T., Carollo, S., Eagan, M.,

Bowcock, A.M. & Krueger, J.G. (2005). Getting under the skin: the immunogenetics of

Boyman, O., Hefti, H.P., Conrad, C., Nickoloff, B.J., Suter, M. & Nestle, F.O. (2004).

Bragulla, H.H. & Homberger, D.G. (2009). Structure and functions of keratin proteins in

Breban, M., Fernandez-Sueiro, J.L., Richardson, J.A., Hadavand, R.R., Maika, S.D., Hammer,

Bullard, D.C., Scharffetter-Kochanek, K., McArthur, M.J., Chosay, J.G., McBride, M.E.,

Carroll, J.M., Crompton, T., Seery, J.P. & Watt, F.M. (1997). Transgenic mice expressing IFN-

Carroll, J.M., Romero, M.R. & Watt, F.M. (1995). Suprabasal integrin expression in the

resembling psoriasis. *Cell,* Vol. 83, No. 6, (Dec 15), pp. 957-968.

psoriatic lesions. *J Cell Biol,* Vol. 135, No. 1, (Oct), pp. 227-239.

role in epidermal function. *Cell,* Vol. 104, No. 1, (Jan 12), pp. 9-19.

psoriasis. *Nat Rev Immunol,* Vol. 5, No. 9, (Sep), pp. 699-711.

P.E., Smith, G.M. & Pringle, J.H. (2004). The development and characterization of an in vitro model of psoriasis. *J Invest Dermatol,* Vol. 123, No. 5, (Nov), pp. 892-901. Ben-Arye, E., Ziv, M., Frenkel, M., Lavi, I. & Rosenman, D. (2003). Complementary medicine

and psoriasis: linking the patient's outlook with evidence-based medicine.

protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of

Foster, D., Haldeman, B.A., Hammond, A., Haugen, H., Jelinek, L., Kelly, J.D., Madden, K., Maurer, M.F., Parrish-Novak, J., Prunkard, D., Sexson, S., Sprecher, C., Waggie, K., West, J., Whitmore, T.E., Yao, L., Kuechle, M.K., Dale, B.A. & Chandrasekher, Y.A. (2001). Interleukin 20: discovery, receptor identification, and

Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. *J Exp Med,* Vol. 199, No. 5,

simple, stratified, keratinized and cornified epithelia. *J Anat,* Vol. 214, No. 4, (Apr),

R.E. & Taurog, J.D. (1996). T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. *J Immunol,* Vol.

Montgomery, C.A. & Beaudet, A.L. (1996). A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice. *Proc Natl Acad Sci U S A,* Vol. 93,

gamma in the epidermis have eczema, hair hypopigmentation, and hair loss. *J* 

epidermis of transgenic mice results in developmental defects and a phenotype

represents a key component in the fight against psoriasis.

*Dermatology,* Vol. 207, No. 3, pp. 302-307.

(Mar 1), pp. 731-736.

156, No. 2, (Jan 15), pp. 794-803.

No. 5, (Mar 5), pp. 2116-2121.

*Invest Dermatol,* Vol. 108, No. 4, (Apr), pp. 412-422.

pp. 516-559.

**5. References** 


Psoriatic Skin Models: A Need for the Pharmaceutical Industry 61

Michel, M., L'Heureux, N., Pouliot, R., Xu, W., Auger, F.A. & Germain, L. (1999).

Mizutani, H., Yamanaka, K., Konishi, H. & Murakami, T. (2003). Animal models of psoriasis and pustular psoriasis. *Arch Dermatol Res,* Vol. 295 Suppl 1, No. (Apr), pp. S67-68. Nagarajan, P., Parikh, N., Garrett-Sinha, L.A. & Sinha, S. (2009). Ets1 induces dysplastic

Nestle, F.O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., Burg, G., Liu,

interferon-alpha production. *J Exp Med,* Vol. 202, No. 1, (Jul 4), pp. 135-143. Nijsten, T., Margolis, D.J., Feldman, S.R., Rolstad, T. & Stern, R.S. (2005). Traditional

Poulin, Y., Papp, K.A., Wasel, N.R., Andrew, R., Fraquelli, E., Bernstein, G. & Chan, D.

Rashmi, R., Rao, K.S. & Basavaraj, K.H. (2009). A comprehensive review of biomarkers in

Raychaudhuri, S.P., Dutt, S., Raychaudhuri, S.K., Sanyal, M. & Farber, E.M. (2001). Severe

Saiag, P., Coulomb, B., Lebreton, C., Bell, E. & Dubertret, L. (1985). Psoriatic fibroblasts

Sano, S., Chan, K.S., Carbajal, S., Clifford, J., Peavey, M., Kiguchi, K., Itami, S., Nickoloff, B.J.

Schon, M.P. (1999). Animal models of psoriasis - what can we learn from them? *J Invest* 

Schon, M.P. (2008). Animal models of psoriasis: a critical appraisal. *Exp Dermatol,* Vol. 17,

Schon, M.P. & Boehncke, W.H. (2005). Psoriasis. *N Engl J Med,* Vol. 352, No. 18, (May 5), pp.

Schon, M.P., Schon, M., Warren, H.B., Donohue, J.P. & Parker, C.M. (2000). Cutaneous

Simpson, G.L., Yelverton, C.B., Rittenberg, S. & Feldman, S.R. (2006). Do utilization

Stern, R.S., Nijsten, T., Feldman, S.R., Margolis, D.J. & Rolstad, T. (2004). Psoriasis is

inflammatory disorder in integrin alphaE (CD103)-deficient mice. *J Immunol,* Vol.

management controls for phototherapy increase the prescription of biologics? *J* 

common, carries a substantial burden even when not extensive, and is associated

deletion of IKK2. *Nature,* Vol. 417, No. 6891, (Jun 20), pp. 861-866.

psoriasis. *Clin Exp Dermatol,* Vol. 34, No. 6, (Aug), pp. 658-663.

vitro. *Science,* Vol. 230, No. 4726, (Nov 8), pp. 669-672.

*Dermatol,* Vol. 112, No. 4, (Apr), pp. 405-410.

*Dermatolog Treat,* Vol. 17, No. 6, pp. 359-361.

*Vitro Cell Dev Biol Anim,* Vol. 35, No. 6, (Jun), pp. 318-326.

*PLoS One,* Vol. 4, No. 1, pp. e4179.

12, (Dec), pp. 1368-1375.

5, (May), pp. 931-939.

Vol. 11, No. 1, (Jan), pp. 43-49.

165, No. 11, (Dec 1), pp. 6583-6589.

No. 8, (Aug), pp. 703-712.

1899-1912.

Characterization of a new tissue-engineered human skin equivalent with hair. *In* 

changes when expressed in terminally-differentiating squamous epidermal cells.

Y.J. & Gilliet, M. (2005). Plasmacytoid predendritic cells initiate psoriasis through

systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. *J Am Acad Dermatol,* Vol. 52, No. 3 Pt 1, (Mar), pp. 434-444. Pasparakis, M., Courtois, G., Hafner, M., Schmidt-Supprian, M., Nenci, A., Toksoy, A.,

Krampert, M., Goebeler, M., Gillitzer, R., Israel, A., Krieg, T., Rajewsky, K. & Haase, I. (2002). TNF-mediated inflammatory skin disease in mice with epidermis-specific

(2010). A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. *Int J Dermatol,* Vol. 49, No.

combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation. *Br J Dermatol,* Vol. 144, No.

induce hyperproliferation of normal keratinocytes in a skin equivalent model in

& DiGiovanni, J. (2005). Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. *Nat Med,*


Hansson, L., Backman, A., Ny, A., Edlund, M., Ekholm, E., Ekstrand Hammarstrom, B.,

Hobbs, R.M., Silva-Vargas, V., Groves, R. & Watt, F.M. (2004). Expression of activated MEK1

Jean, J., Soucy, J. & Pouliot, R. (2011). Effects of Retinoic Acid in Keratinocyte Proliferation and Differentiation in a Psoriatic Skin Model. *Tissue Eng Part A,* Vol. No. (Mar 18), Karlsson, T., Rollman, O., Vahlquist, A. & Torma, H. (2004). Immunofluorescence

Keith, J.C., Jr., Sainz, I.M., Isordia-Salas, I., Pixley, R.A., Leathurby, Y., Albert, L.M. & Colman,

Kess, D., Peters, T., Zamek, J., Wickenhauser, C., Tawadros, S., Loser, K., Varga, G., Grabbe, S.,

a murine model of psoriasis. *J Immunol,* Vol. 171, No. 11, (Dec 1), pp. 5697-5706. Klotz, J., Muir, L., Cameron, C. & Delaney, L. (2005). Monitoring a remote phototherapy unit

Konstantinova, N.V., Duong, D.M., Remenyik, E., Hazarika, P., Chuang, A. & Duvic, M.

Kormeili, T., Lowe, N.J. & Yamauchi, P.S. (2004). Psoriasis: immunopathogenesis and

Krueger, G., Koo, J., Lebwohl, M., Menter, A., Stern, R.S. & Rolstad, T. (2001). The impact of

membership survey. *Arch Dermatol,* Vol. 137, No. 3, (Mar), pp. 280-284. Krueger, G.G., Langley, R.G., Leonardi, C., Yeilding, N., Guzzo, C., Wang, Y., Dooley, L.T. &

treatment of psoriasis. *N Engl J Med,* Vol. 356, No. 6, (Feb 8), pp. 580-592. Krueger, J.G. (2002). The immunologic basis for the treatment of psoriasis with new biologic agents. *J Am Acad Dermatol,* Vol. 46, No. 1, (Jan), pp. 1-23; quiz 23-26. Krueger, J.G. & Bowcock, A. (2005). Psoriasis pathophysiology: current concepts of pathogenesis. *Ann Rheum Dis,* Vol. 64 Suppl 2, No. (Mar), pp. ii30-ii36. Lowes, M.A., Bowcock, A.M. & Krueger, J.G. (2007). Pathogenesis and therapy of psoriasis.

HLA-B27 transgenic rat. *Arthritis Res Ther,* Vol. 7, No. 4, pp. R769-776.

via telemedicine. *J Cutan Med Surg,* Vol. 9, No. 2, (Apr), pp. 47-53.

of p40. *J Invest Dermatol,* Vol. 117, No. 3, (Sep), pp. 618-626.

*Dermatol,* Vol. 151, No. 1, (Jul), pp. 3-15.

*Nature,* Vol. 445, No. 7130, (Feb 22), pp. 866-873.

Menter, A. & Stoff, B. (2010). *Psoriasis* London

*Dermatol Ther,* Vol. 17 Suppl 1, No. pp. 6-15.

*Acta Derm Venereol,* Vol. 84, No. 5, pp. 363-369.

359-382,

Tornell, J., Wallbrandt, P., Wennbo, H. & Egelrud, T. (2002). Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. *J Invest Dermatol,* Vol. 118, No. 3, (Mar), pp. 444-449. Harding, C.R. (2004). The stratum corneum: structure and function in health and disease.

in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. *J Invest Dermatol,* Vol. 123, No. 3, (Sep), pp. 503-515. Jean, J., Lapointe, M., Soucy, J. & Pouliot, R. (2009). Development of an in vitro psoriatic skin model by tissue engineering. *J Dermatol Sci,* Vol. 53, No. 1, (Jan), pp. 19-25. Jean, J. & Pouliot, R. (2010), In vivo and in vitro models of psoriasis, In: *Tissue engineering*,pp.

localization of nuclear retinoid receptors in psoriasis versus normal human skin.

R.W. (2005). A monoclonal antibody against kininogen reduces inflammation in the

Nischt, R., Sunderkotter, C., Muller, W., Krieg, T. & Scharffetter-Kochanek, K. (2003). CD4+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in

(1996). Interleukin-8 is induced in skin equivalents and is highest in those derived from psoriatic fibroblasts. *J Invest Dermatol,* Vol. 107, No. 4, (Oct), pp. 615-621. Kopp, T., Kieffer, J.D., Rot, A., Strommer, S., Stingl, G. & Kupper, T.S. (2001). Inflammatory

skin disease in K14/p40 transgenic mice: evidence for interleukin-12-like activities

evolving immunomodulators and systemic therapies; U.S. experiences. *Br J* 

psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-

Lebwohl, M. (2007). A human interleukin-12/23 monoclonal antibody for the


**Part 2** 

**Clinical Presentation** 

with widespread treatment dissatisfaction. *J Investig Dermatol Symp Proc,* Vol. 9, No. 2, (Mar), pp. 136-139.

